MRI INTERVENTIONS INC IRVINE, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain, today announced the first stereotactic laser ablation of the hippocampus (SLAH) procedure at Yale-New Haven Hospital. By using the ClearPoint Neuro Navigation System and the Monteris NeuroBlate® System in an intra-operative MRI suite, the laser fiber trajectory and target identification was highly accurate, and visible under real time MRI guidance.
"We performed, for the first time at Yale-New Haven Hospital, a successful laser ablation of the hippocampus on a male patient in his mid-40's," said Dr. Dennis Spencer, the Harvey and Kate Cushing Professor, Co-Director of the Yale comprehensive epilepsy program and Director of epilepsy surgery at Yale University School of Medicine, and Yale-New Haven Hospital. Dr. Spencer is a pioneer of the neocortical sparing medial temporal lobectomy and amygdala hippocampotomy. "Utilizing the ClearPoint and Monteris systems for this procedure allowed us to ablate the hippocampus with sub-millimetric accuracy and then send the patient home two days after his surgery. By ablating the suspected source of seizures, we aim to dramatically improve this patient's quality of life," said Dr. Spencer.
The ClearPoint Neuro Navigation System is the only technology that enables minimally-invasive neurosurgery under continuous MRI guidance, offering surgeons real-time direction and a direct view of the inside of a patient's brain during a procedure. MRI provides superior visualization of the brain's tissue compared to other imaging technologies.
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. The ClearPoint system, which has received 510(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of our products; our ability to successfully expand, and achieve full productivity from, our sales, clinical support and marketing capabilities; our ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of our cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact our commercialization efforts. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2014, as well as the Company's Form 10-Q for the quarter ended March 31, 2015, which have been filed with the Securities and Exchange Commission.
CONTACT: MRI Interventions, Inc.
Wendelin Maners, Vice President Marketing
949-900-6833
